Taking stock of the drug industry, from the lab to the medicine chestMay 11, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer APStock STAT+ | Wyden decries 'astonishingly low' tax rates for pharma companies as he probes business maneuvers "Big Pharma gets us coming and going - they charge Americans sky-high prices and they pay absolute rock-bottom taxes," said Sen. Ron Wyden By Ed Silverman STAT+ | Senate panel passes a suite of drug pricing bills — but fails to advance one major PBM reform A Senate panel passed a package of bills aimed at speeding generic drug competition and reining in drug middlemen business practices. By John Wilkerson STAT+ | How the FDA's pandemic flexibilities boosted mental health apps — and what happens now STAT spoke to mental health app makers that took advantage of the FDA's loosened regulations during the pandemic about their future plans. By Mario Aguilar Sammy Kimball for STAT Listen: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry This episode, we explain why it's a massive week for Sarepta Therapeutics, the FDA, and the future of gene therapies for rare diseases. By Damian Garde and Meg Tirrell and Adam Feuerstein STAT+ | Telework helps FDA compete for scientists. What if it's no longer an option? FDA's difficult task of hiring in-demand scientists could become even harder if federal workers must return to the office. By John Wilkerson More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments